All Adolfo García-Sastre, articles
-
NewsMount Sinai awarded five-year, $20.7 million vaccine development agreement to advance next-generation technologies against respiratory threats
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a five-year project agreement to develop Vaccine Immunoengineering for Targeted Antigen Presentation and Layered Control (VITAL), a research program exploring an improved approach to vaccination against respiratory pathogens.